BioScience Health Innovations, Inc.
NOTR
$9.01
-$0.99-9.90%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 208.73% | 358.81% | 611.06% | 732.08% | 762.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 208.73% | 358.81% | 611.06% | 732.08% | 762.34% |
| Cost of Revenue | 373.92% | 546.98% | 845.18% | 957.34% | 1,065.98% |
| Gross Profit | 170.21% | 324.94% | 572.86% | 694.03% | 711.39% |
| SG&A Expenses | 66.04% | 125.21% | 152.85% | 248.27% | 328.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 107.04% | 163.15% | 189.93% | 284.37% | 367.57% |
| Operating Income | 134.59% | 116.45% | 71.51% | -30.98% | -123.95% |
| Income Before Tax | 134.59% | 113.18% | 76.69% | 1.18% | -47.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 134.59% | 113.18% | 76.69% | 1.18% | -47.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 134.59% | 113.18% | 76.69% | 1.18% | -47.51% |
| EBIT | 134.59% | 116.45% | 71.51% | -30.98% | -123.95% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 121.05% | 105.33% | 92.65% | 74.78% | 49.74% |
| Normalized Basic EPS | 120.00% | 104.72% | 92.16% | 74.47% | 49.15% |
| EPS Diluted | 117.09% | 92.31% | 83.67% | 65.04% | 38.10% |
| Normalized Diluted EPS | 120.00% | 104.72% | 92.16% | 74.47% | 49.15% |
| Average Basic Shares Outstanding | 24.38% | 60.00% | 125.67% | 283.98% | 330.24% |
| Average Diluted Shares Outstanding | 25.63% | 60.00% | 125.67% | 283.98% | 330.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |